<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00551473</url>
  </required_header>
  <id_info>
    <org_study_id>LAV110285</org_study_id>
    <nct_id>NCT00551473</nct_id>
  </id_info>
  <brief_title>Open-label Comparison of 24hr Gastric pH on Days 1, 2, 7 With Once-daily Administration of Lavoltidine 40 mg.</brief_title>
  <official_title>An Open-Label Study of the Development of Pharmacodynamic Tolerance to 7-days Administration of Lavoltidine 40mg</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current treatment for gastroesophageal reflux disease(GERD)confirms an unmet need in
      patients, based on slow onset of action and an inability to provide 24-hour gastric acid
      suppression. Clinical data on lavoltidine demonstrates a rapid onset of action, high potency,
      and prolonged duration of effect after single dose. Since tolerance to the class of compounds
      to which lavoltidine belongs may be dose dependent, the current study is designed to
      determine if 40mg lavoltdine given for 7days develops tolerance.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the degree of pharmacodynamic tolerance following seven days administration of lavoltidine 40mg on gastric pH as assessed by percentage of 24hrs pH&gt;4.</measure>
    <time_frame>seven days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine whether or not significant pharmacodynamic tolerance occurs as early as the second dose of 40mg lavoltidine. Safety and tolerance of seven days administration of lavoltidine 40 mg, in healthy male volunteers.</measure>
    <time_frame>seven days</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">18</enrollment>
  <condition>Gastroesophageal Reflux Disease</condition>
  <condition>Reflux, Gastroesophageal</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lavoltidine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male, from 18-55 years

          -  Have BMI from 19-30 kg/m2

          -  do not present with abnormal clinical lab findings

          -  are able to tolerate a nasogastric pH electrode.

        Exclusion Criteria:

          -  Helicobacter-positive on a C13 urea breath test

          -  have a baseline median 24-hour gastric pH&gt;3
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Randwick, Sydney</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2007</study_first_submitted>
  <study_first_submitted_qc>October 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2007</study_first_posted>
  <last_update_submitted>May 31, 2012</last_update_submitted>
  <last_update_submitted_qc>May 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacodynamics,</keyword>
  <keyword>tolerance</keyword>
  <keyword>H2 antagonist,</keyword>
  <keyword>AH23844,</keyword>
  <keyword>lavoltidine,</keyword>
  <keyword>gastroesophageal reflux disease (GERD), pharmacokinetics,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

